The market for wet age-related macular degeneration (AMD) is forecasted to expand as the number of diagnosed cases continues to rise. This growth is further fueled by the introduction of new therapies like Ixoberogene soroparvovec (Ixo-vec) by Adverum Biotechnologies, Surabgene lomparvovec (RGX-314) by Regenxbio/AbbVie, and OGX-110. These emerging treatments are expected to contribute to the market’s upward trajectory alongside current therapies.